Moderna Gets FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine

By Michael Dabaie

Moderna Inc. said the U.S. Food and Drug Administration granted Fast Track designation for mRNA-1345, its investigational vaccine against respiratory syncytial virus in adults older than 60.

Respiratory syncytial virus is a common respiratory virus that generally causes cold-like symptoms. In the U.S. and areas with similar climates, RSV infections occur primarily during fall, winter and spring. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.

Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and that fill an unmet medical need.

Moderna shares were up 1.6% to $352 in premarket trading.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

August 03, 2021 09:34 ET (13:34 GMT)

Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024